LB Pharmaceuticals Inc Common Stock
LBRX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.28B
Close$
$9.75
76.1% downside
Current Fair Value
76.1% downsideOvervalued by 76.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.28 Billion |
|---|---|
| Enterprise Value | $1.00 Billion |
| Earnings per Share | $-1 |
| Beta | 0.42 |
| Outstanding Shares | 30,137,000 |
Return
| Return on Equity | -25.78% |
|---|---|
| Return on Assets | -23.69% |
| Return on Invested Capital | -27.64% |
Valuation & Multiples
| P/E Ratio | -13.37 |
|---|---|
| PEG | -5.07 |
| Price to Sales | - |
| Price to Book Ratio | 3.71 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -10.73 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.80
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.62
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.48%▼ 105.58% |
|---|---|
| Total Invested | $5.53M▼ 99.43% |
| Investors Holding | 20▼ 97.00% |
About LB Pharmaceuticals Inc Common Stock
16 employees
CEO: Heather D. Turner
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.